Results
21
Companies with strong growth potential, backed by optimistic outlooks both from analysts and management.
21 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
ADOC | €5.67 | -21.6% | 52.8% | €85.3m | €6.30 | PS14.1x | E63.0% | n/a | Pharmaceuticals & Biotech | ||
ALOKW | €19.74 | 8.7% | -22.3% | €163.1m | €30.30 | PE21.6x | E30.8% | n/a | Capital Goods | ||
VU | €142.10 | 2.3% | 6.8% | €2.3b | €195.20 | PE28.3x | E25.2% | 0.2% | Tech | ||
ALMUN | €0.46 | -7.6% | -84.4% | €4.1m | €1.30 | PB0.3x | E149.2% | n/a | Tech | ||
OSE | €6.54 | 0% | 86.9% | €142.3m | €10.15 | PS63.9x | E5.9% | n/a | Pharmaceuticals & Biotech | ||
FDE | €28.60 | -3.4% | -32.7% | €149.6m | €60.33 | PE19x | E31.9% | n/a | Energy | ||
ALCUR | €6.68 | 9.5% | 165.1% | €38.5m | €8.48 | PE21.4x | E27.5% | n/a | Capital Goods | ||
ALICA | €10.50 | 2.9% | -25.3% | €84.9m | €16.00 | PE15.5x | E26.2% | 1.9% | Tech | ||
MEDCL | €14.60 | 1.4% | 140.5% | €424.3m | €20.70 | PS35.5x | E69.6% | n/a | Pharmaceuticals & Biotech | ||
ALSMA | €3.87 | 4.9% | 52.4% | €20.2m | €5.80 | PE19.1x | E35.2% | n/a | Healthcare | ||
CLA | €1.87 | 1.1% | 5.9% | €106.2m | €4.75 | PE-21.2x | E90.6% | n/a | Software | ||
ALLIX | €7.92 | -3.6% | -29.9% | €51.5m | €16.00 | PS1.5x | E101.6% | n/a | Software | ||
S30 | €1.70 | 6.9% | -41.1% | €181.6m | €2.75 | PB1.6x | E101.6% | n/a | Software | ||
ALECP | €0.34 | 0% | -31.2% | €42.3m | n/a | PE47x | E86.8% | 0% | Media | ||
ALHOP | €21.30 | -1.4% | 20.3% | €61.2m | €30.05 | PE13.4x | E21.6% | 3.1% | Media | ||
ALCIS | €8.52 | 0% | -16.9% | €66.3m | €12.10 | PE20.8x | E56.5% | 1.9% | Commercial Services | ||
ATEME | €3.76 | -5.1% | -60.1% | €43.2m | €8.00 | PB1.1x | E96.4% | n/a | Tech | ||
LSS | €28.00 | -5.7% | 2.8% | €1.1b | €34.75 | PE31.7x | E28.6% | 1.3% | Software | ||
OVH | €5.48 | -4.1% | -41.8% | €1.0b | €9.14 | PS1.1x | E103.7% | n/a | Software | ||
ALPAT | €13.60 | -2.9% | 7.9% | €15.0m | €11.50 | n/a | E92.7% | n/a | Pharmaceuticals & Biotech | ||
EXN | €22.90 | -3.2% | 19.0% | €2.1b | €24.50 | PE48.1x | E28.4% | 0% | Software |